Kentucky Risperdal Lawsuit Settles for $15.5 Million
- Last Updated: August 13th, 2023
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Kentucky Risperdal Lawsuit Settles for $15.5 Million
A lawsuit brought by the Kentucky Attorney General alleging that Janssen Pharmaceuticals, the manufacturer of the antipsychotic drug Risperdal, marketed the medication as an appropriate treatment for dementia in non-schizophrenic elderly patients has been settled for $15.5 million.
According to court documents, Janssen Pharmaceuticals even went so far as to establish an elder care sales force, despite the fact that the company’s own study conducted in 1997 showed that Risperdal actually doubled the risk of death among the elderly.
Risperdal’s label did not disclose this risk to the public until 2003, and in 2013, Janssen pleaded guilty to federal charges of misbranding the drug regarding the promotions to the elderly.
The lawsuit alleged that Janssen did not disclose the risks associated with Risperdal to consumers, and also marketed the drug for uses other than those that were originally approved by the U.S. Food and Drug Administration (FDA), resulting in excessive costs to Medicare and Medicaid in the state.
Table of Contents
What is Risperdal?
Risperdal is an anti-psychotic drug first approved by the U.S. Food and Drug Administration in 1993 to treat adults with schizophrenia.
In 2006 and 2007, the FDA approved additional uses for Risperdal, including the treatment of bipolar disorder in adults and juveniles, schizophrenia in children, and certain behavioral symptoms in children with autism.
The Kentucky lawsuit alleged that even though Risperdal was approved for use in children with Attention Deficit Hyperactivity Disorder (ADHD) in 2007, Janssen actively marketed Risperdal to children and the youth market long before the medication was formally approved for that category of patients.
One Risperdal side effect that has occurred in young males is Risperdal gynecomastia, the development of male breasts stemming from a hormonal imbalance triggered by Risperdal.
Risperdal lawsuits brought by males who claim that their Risperdal prescription caused them to develop gynecomastia continue to be filed and move through courts across the U.S.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
